Novel Growth Factor Combination for Improving Rotator Cuff Repair: A Rat In Vivo Study.


Journal

The American journal of sports medicine
ISSN: 1552-3365
Titre abrégé: Am J Sports Med
Pays: United States
ID NLM: 7609541

Informations de publication

Date de publication:
03 2022
Historique:
pubmed: 22 2 2022
medline: 6 4 2022
entrez: 21 2 2022
Statut: ppublish

Résumé

The lack of healing at the repaired tendon-bone interface is an important cause of failure after rotator cuff repair. While augmentation with growth factors (GFs) has demonstrated promise, the ideal combination must target all 3 tissue types at the tendon-bone interface. The GF combination of transforming growth factor beta 1, Insulin-like growth factor 1, and parathyroid hormone will promote tenocyte proliferation and differentiation and improve the biomechanical and histological quality of the repaired tendon-bone interface. Controlled laboratory study. In vitro, human tenocytes were cultured in the presence of the GF combination for 72 hours, and cell growth assays and the expression of genes specific to tendon, cartilage, and bone were analyzed. In vivo, adult rats (N = 46) underwent detachment and repair of the left supraspinatus tendon. A PVA-tyramine gel was used to deliver the GF combination to the tendon-bone interface. Histological, biomechanical, and RNA microarray analysis was performed at 6 and 12 weeks after surgery. Immunohistochemistry for type II and X collagen was performed at 12 weeks. When treated with the GF combination in vitro, human tenocytes proliferated 1.5 times more than control ( The GF combination promoted protendon and cartilage responses in human tenocytes in vitro; it also improved the histological appearance and mechanical properties of the repair in vivo. Microarrays of the tendon-bone interface identified inflammatory and mineralization pathways affected by the GF combination, providing novel therapeutic targets for further research. The use of this GF combination is translatable to patients and may improve healing after rotator cuff repair.

Sections du résumé

BACKGROUND
The lack of healing at the repaired tendon-bone interface is an important cause of failure after rotator cuff repair. While augmentation with growth factors (GFs) has demonstrated promise, the ideal combination must target all 3 tissue types at the tendon-bone interface.
HYPOTHESIS
The GF combination of transforming growth factor beta 1, Insulin-like growth factor 1, and parathyroid hormone will promote tenocyte proliferation and differentiation and improve the biomechanical and histological quality of the repaired tendon-bone interface.
STUDY DESIGN
Controlled laboratory study.
METHODS
In vitro, human tenocytes were cultured in the presence of the GF combination for 72 hours, and cell growth assays and the expression of genes specific to tendon, cartilage, and bone were analyzed. In vivo, adult rats (N = 46) underwent detachment and repair of the left supraspinatus tendon. A PVA-tyramine gel was used to deliver the GF combination to the tendon-bone interface. Histological, biomechanical, and RNA microarray analysis was performed at 6 and 12 weeks after surgery. Immunohistochemistry for type II and X collagen was performed at 12 weeks.
RESULTS
When treated with the GF combination in vitro, human tenocytes proliferated 1.5 times more than control (
CONCLUSION
The GF combination promoted protendon and cartilage responses in human tenocytes in vitro; it also improved the histological appearance and mechanical properties of the repair in vivo. Microarrays of the tendon-bone interface identified inflammatory and mineralization pathways affected by the GF combination, providing novel therapeutic targets for further research.
CLINICAL RELEVANCE
The use of this GF combination is translatable to patients and may improve healing after rotator cuff repair.

Identifiants

pubmed: 35188803
doi: 10.1177/03635465211072557
doi:

Substances chimiques

Intercellular Signaling Peptides and Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1044-1053

Auteurs

Mark Zhu (M)

Bone and Joint Laboratory, School of Medicine, University of Auckland, Auckland, New Zealand.

Mei Lin Tay (M)

Bone and Joint Laboratory, School of Medicine, University of Auckland, Auckland, New Zealand.

Khoon S Lim (KS)

Department of Orthopaedic Surgery and Musculoskeletal Medicine, University of Otago, Christchurch, New Zealand.

Scott M Bolam (SM)

Bone and Joint Laboratory, School of Medicine, University of Auckland, Auckland, New Zealand.

Donna Tuari (D)

Bone and Joint Laboratory, School of Medicine, University of Auckland, Auckland, New Zealand.

Karen Callon (K)

Bone and Joint Laboratory, School of Medicine, University of Auckland, Auckland, New Zealand.

Michael Dray (M)

Department of Pathology, Waikato Hospital, Hamilton, New Zealand.

Jillian Cornish (J)

Bone and Joint Laboratory, School of Medicine, University of Auckland, Auckland, New Zealand.

Tim B F Woodfield (TBF)

Department of Orthopaedic Surgery and Musculoskeletal Medicine, University of Otago, Christchurch, New Zealand.

Jacob T Munro (JT)

Bone and Joint Laboratory, School of Medicine, University of Auckland, Auckland, New Zealand.
Department of Orthopaedic Surgery, Auckland City Hospital, Auckland, New Zealand.

Brendan Coleman (B)

Department of Orthopaedic Surgery, Counties Manukau Health, Auckland, New Zealand.

David S Musson (DS)

Bone and Joint Laboratory, School of Medicine, University of Auckland, Auckland, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH